BG1430U1 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
BG1430U1
BG1430U1 BG1811U BG181110U BG1430U1 BG 1430 U1 BG1430 U1 BG 1430U1 BG 1811 U BG1811 U BG 1811U BG 181110 U BG181110 U BG 181110U BG 1430 U1 BG1430 U1 BG 1430U1
Authority
BG
Bulgaria
Prior art keywords
pharmaceutical formulation
hifn
formulation
pharmacopoeial
stabilizers
Prior art date
Application number
BG1811U
Other languages
Bulgarian (bg)
Inventor
Иван ИВАНОВ
Геновева НАЧЕВА
Hans-Guenther Grigoleit
Original Assignee
Иван ИВАНОВ
Геновева НАЧЕВА
Hans-Guenther Grigoleit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иван ИВАНОВ, Геновева НАЧЕВА, Hans-Guenther Grigoleit filed Critical Иван ИВАНОВ
Priority to BG1811U priority Critical patent/BG1430U1/en
Publication of BG1430U1 publication Critical patent/BG1430U1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The utility model relates to a pharmaceutical formulation which suppresses the activity of endogenous human interferon-? (hIFN-?) in diseases associated with abnormal hIFN-? production, in particular, auto-immune diseases and post-transplant atherosclerosis. The formulation presents in a lyophilized state for parenteral administration and includes recombinant protein, pharmacopoeial buffers and stabilizers.
BG1811U 2010-06-25 2010-06-25 Pharmaceutical formulation BG1430U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BG1811U BG1430U1 (en) 2010-06-25 2010-06-25 Pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG1811U BG1430U1 (en) 2010-06-25 2010-06-25 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BG1430U1 true BG1430U1 (en) 2011-04-29

Family

ID=45877018

Family Applications (1)

Application Number Title Priority Date Filing Date
BG1811U BG1430U1 (en) 2010-06-25 2010-06-25 Pharmaceutical formulation

Country Status (1)

Country Link
BG (1) BG1430U1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US82138A (en) * 1868-09-15 Improvement in liquid-metees
WO1995030435A2 (en) * 1994-05-10 1995-11-16 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
CA2361081A1 (en) * 1999-01-20 2000-07-27 The University Of Queensland Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US82138A (en) * 1868-09-15 Improvement in liquid-metees
WO1995030435A2 (en) * 1994-05-10 1995-11-16 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
CA2361081A1 (en) * 1999-01-20 2000-07-27 The University Of Queensland Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis

Similar Documents

Publication Publication Date Title
MX2019010226A (en) Lipid nanoparticle compositions and methods for mrna delivery.
EP4276180A3 (en) Clostridium histolyticum enzyme
NZ600709A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
PH12016500011A1 (en) Cells for producing recombinant iduronate-2-sulfatase
PH12015501421B1 (en) Long-acting formulations of insulins
WO2012047733A3 (en) Treatment of acne by conditioned media
BR112013023756A2 (en) mutant cells for protein secretion and lignocellulose degradation
NZ702801A (en) Treatment of sanfilippo syndrome type b
WO2012000103A8 (en) Methods of targeting pten mutant diseases and compositions therefor
NZ610556A (en) Stem cell suspension
NZ623294A (en) Stabilized alpha-galactosidase and uses thereof
MX2013002725A (en) Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle.
NZ597580A (en) Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
AU2016219650A1 (en) Compositions and methods for extended therapy with aminopyridines
EP2558124A4 (en) Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
BR112014015933A2 (en) methods and materials to reduce recombinant protein degradation
WO2012115903A3 (en) Yeast strain for the production of proteins with modified o-glycosylation
BR112014010053A2 (en) Isoprene synthase variants with enhanced solubility for isoprene production
BR112014021326A2 (en) cell for protein expression, method for reducing peptide amidation activity in a given cell, use of a cell
WO2014072720A3 (en) Cell differentiation
BG1430U1 (en) Pharmaceutical formulation
IN2014MN02461A (en)
MX2012012489A (en) Preparation of polypeptides and salts thereof.
EP3065705A4 (en) Compositions and methods for administration of an enzyme to a subject's airway
WO2012129449A3 (en) High level production of recombinant proteins